Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BORRELIA: Phase 2 Study of Bortezomib in Relapsed/Refractory Immune Thrombocytopenia
KCT0007758Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Oct 2022
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in immune thrombocytopenia (ITP), sponsored by Boryung. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
bortezomib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on KCT0007758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007758.